The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis

[1] Blauvelt A(2022)Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial J Am Acad Dermatol 86 104-112

[2] Silverberg JI(2020)Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials Br J Dermatol 183 242-255

[3] Lynde CW(2019)A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis Rheumatol (United Kingdom) 58 1755-1766

[4] Simpson EL(2022)Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis JAMA Dermatol 158 523-532

[5] Lacour JP(2021)Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis Front Med (Lausanne) 8 777-784

[6] Spelman L(2015)The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med 162 44-47

[7] Bechman K(1980)Diagnostic features of atopic dermatitis Acta Derm Venereol 60 1117-1145

[8] Subesinghe S(2016)Clinical practice guidelines for the management of atopic dermatitis 2016 J Dermatol 43 1-8

[9] Norton S(2019)RoB 2: a revised tool for assessing risk of bias in randomised trials BMJ 366 325-337

[10] Drucker AM(2000)WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility Stat Comput 10 1309-1317

[1] Blauvelt A(2022)Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial J Am Acad Dermatol 86 104-112

[2] Silverberg JI(2020)Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials Br J Dermatol 183 242-255

[3] Lynde CW(2019)A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis Rheumatol (United Kingdom) 58 1755-1766

[4] Simpson EL(2022)Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis JAMA Dermatol 158 523-532

[5] Lacour JP(2021)Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis Front Med (Lausanne) 8 777-784

[6] Spelman L(2015)The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med 162 44-47

[7] Bechman K(1980)Diagnostic features of atopic dermatitis Acta Derm Venereol 60 1117-1145

[8] Subesinghe S(2016)Clinical practice guidelines for the management of atopic dermatitis 2016 J Dermatol 43 1-8

[9] Norton S(2019)RoB 2: a revised tool for assessing risk of bias in randomised trials BMJ 366 325-337

[10] Drucker AM(2000)WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility Stat Comput 10 1309-1317